Literature DB >> 8257427

Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.

K J Rieger1, N Saez-Servent, M P Papet, J Wdzieczak-Bakala, J L Morgat, J Thierry, W Voelter, M Lenfant.   

Abstract

The degradation of N-Ac-Ser-Asp-Lys-Pro (AcSDKP), a negative regulator controlling the proliferation of the haematopoietic stem cell, by enzymes present in human plasma, has been investigated. Radiolabelled AcSD[4-3H]KP ([3H]AcSDKP, 1 mM) was completely metabolized in human plasma with a half-life of 80 min, leading exclusively to the formation of radiolabelled lysine. The cleavage of AcSDKP was insensitive to classical proteinase inhibitors including leupeptin, but sensitive to metalloprotease inhibitors. The degradation was completely blocked by specific inhibitors of angiotensin I-converting enzyme (ACE; kininase II; peptidyldipeptide hydrolase, EC 3.4.15.1), showing that the first step of the hydrolysis was indeed due to ACE. In dialysed plasma, the hydrolysis proceeded at only 17% of the maximal rate, whereas addition of 20 mM NaCl led to the recovery of the initial rate observed with normal plasma. Hydrolysis of AcSDKP by commercial rabbit lung ACE generated the C-terminal dipeptide Lys-Pro. Thus, ACE cleaves AcSDKP by a dipeptidyl carboxypeptidase activity. In fact the formation of Lys-Pro was observed when AcSDKP was incubated in human plasma in the presence of HgCl2. These results suggest that ACE is involved in the first limiting step of AcSDKP degradation in human plasma. The second step seems to be under the control of a leupeptin- and E-64-insensitive, HgCl2-sensitive plasmatic enzyme.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257427      PMCID: PMC1137706          DOI: 10.1042/bj2960373

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  15 in total

1.  Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation.

Authors:  A E Bogden; P Carde; E D de Paillette; J P Moreau; M Tubiana; E Frindel
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

2.  Inhibitor of stem cell proliferation in normal bone marrow.

Authors:  B I Lord; K J Mori; E G Wright; L G Lajtha
Journal:  Br J Haematol       Date:  1976-11       Impact factor: 6.998

3.  Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure.

Authors:  M Lenfant; J Wdzieczak-Bakala; E Guittet; J C Prome; D Sotty; E Frindel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

4.  Inhibition of CFU entry into cycle by a bone marrow extract.

Authors:  E Frindel; M Guigon
Journal:  Exp Hematol       Date:  1977-01       Impact factor: 3.084

5.  Novel activity of human angiotensin I converting enzyme: release of the NH2- and COOH-terminal tripeptides from the luteinizing hormone-releasing hormone.

Authors:  R A Skidgel; E G Erdös
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

6.  Electrophoretic mobilities of peptides on paper and their use in the determination of amide groups.

Authors:  R E Offord
Journal:  Nature       Date:  1966-08-06       Impact factor: 49.962

7.  Involvement of thymosin beta 4 and endoproteinase Asp-N in the biosynthesis of the tetrapeptide AcSerAspLysPro a regulator of the hematopoietic system.

Authors:  C Grillon; K Rieger; J Bakala; D Schott; J L Morgat; E Hannappel; W Voelter; M Lenfant
Journal:  FEBS Lett       Date:  1990-11-12       Impact factor: 4.124

8.  Angiotensin convertase activities in human alveolar macrophages: effects of cigarette smoking and sarcoidosis.

Authors:  L M Hinman; C Stevens; R A Matthay; J Bernard; L Gee
Journal:  Science       Date:  1979-07-13       Impact factor: 47.728

9.  Substrate specificity and kinetic characteristics of angiotensin converting enzyme.

Authors:  P Bünning; B Holmquist; J F Riordan
Journal:  Biochemistry       Date:  1983-01-04       Impact factor: 3.162

10.  Aminopeptidase A activity of the murine B-lymphocyte differentiation antigen BP-1/6C3.

Authors:  Q Wu; L Li; M D Cooper; M Pierres; J P Gorvel
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

View more
  13 in total

Review 1.  Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme.

Authors:  Sebastien Fuchs; Kristen Frenzel; Hong D Xiao; Jonathan W Adams; Hui Zhao; George Keshelava; Lu Teng; Kenneth E Bernstein
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 2.  The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis.

Authors:  Xiao Z Shen; Kenneth E Bernstein
Journal:  Cell Cycle       Date:  2011-05-01       Impact factor: 4.534

3.  The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice.

Authors:  C R Esther; E M Marino; T E Howard; A Machaud; P Corvol; M R Capecchi; K E Bernstein
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

4.  Purified angiotensin converting enzyme from Rana esculenta ovary influences ovarian steroidogenesis in vitro.

Authors:  A Miano; L Quassinti; E Maccari; O Murri; D Amici; M Bramucci
Journal:  J Physiol Biochem       Date:  2003-12       Impact factor: 4.158

5.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

6.  Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.

Authors:  Jean Boutonnat; Anne-Marie Faussat; Jean-Pierre Marie; Jérôme Bignon; Johanna Wdzieczak-Bakala; Magali Barbier; Josiane Thierry; Xavier Ronot; Pierre-Emmanuel Colle
Journal:  BMC Cancer       Date:  2005-09-20       Impact factor: 4.430

7.  Resistance of dialyzed patients to erythropoietin.

Authors:  Michelle Teodoro Alves; Sandra Simone Vilaça; Maria das Graças Carvalho; Ana Paula Fernandes; Luci Maria Sant'Ana Dusse; Karina Braga Gomes
Journal:  Rev Bras Hematol Hemoter       Date:  2015-02-17

8.  The actin-sequestering protein thymosin beta-4 is a novel target of hypoxia-inducible nitric oxide and HIF-1α regulation.

Authors:  Yun-Kyoung Ryu; Joo-Hyun Kang; Eun-Yi Moon
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240

9.  Angiotensin-converting enzyme defines matrikine-regulated inflammation and fibrosis.

Authors:  Philip J O'Reilly; Qiang Ding; Samia Akthar; Guoqiang Cai; Kristopher R Genschmer; Dhiren F Patel; Patricia L Jackson; Liliana Viera; Mojtaba Roda; Morgan L Locy; Ellen A Bernstein; Clare M Lloyd; Kenneth E Bernstein; Robert J Snelgrove; J Edwin Blalock
Journal:  JCI Insight       Date:  2017-11-16

10.  Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.

Authors:  Geoffrey Masuyer; Ross G Douglas; Edward D Sturrock; K Ravi Acharya
Journal:  Sci Rep       Date:  2015-09-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.